MOESM1 of Glioma SOX2 Expression Decreased after Adjuvant Therapy

Wei Yu,Xiaoqiu Ren,Chunxiu Hu,Yinuo Tan,Yongjie Shui,Zexin Chen,Lili Zhang,Jiaping Peng,Qichun Wei

DOI: https://doi.org/10.6084/m9.figshare.10297094

2019-01-01

Abstract:Additional file 1: Table S1. SOX2 mRNA expression in 153 glioma cases in the TCGA database.

What problem does this paper attempt to address?

Glioma SOX2 Expression Decreased after Adjuvant Therapy.

Wei Yu,Xiaoqiu Ren,Chunxiu Hu,Yinuo Tan,Yongjie Shui,Zexin Chen,Lili Zhang,Jiaping Peng,Qichun Wei

DOI: https://doi.org/10.1186/s12885-019-6292-y

IF: 4.638

2019-01-01

BMC Cancer

Abstract:Background SOX2 is regarded as an important marker in stem cell. The change of SOX2 expression after adjuvant therapy in high grade glioma (HGG) remains unknown so far. Few patients with recurrent glioma have opportunity to undergo operation once again, so the recurrent glioma samples are scarce. This study tries to analyze SOX2 expression in paired primary and recurrent HGG, aims to better understand the transformation law of SOX2 after adjuvant therapy in HGG. Methods Twenty-four recurrent HGG patients who undergone a second resection were included. 16 patients received adjuvant therapy, the remaining 8 patients didn’t receive any adjuvant therapy at all. The protein expression of SOX2 in paired primary and recurrent HGG was tested by immunohistochemistry. The statistical analysis was conducted by IBM SPSS Statistics 19.0. Results In primary HGG, SOX2 expression of 3 + , 2 + , 1+ and 0+ were seen in 20 (83.3%), 1 (4.2%), 1 (4.2%) and 2 cases (8.3%), respectively. The expression of SOX2 was decreased in recurrent HGG compared to the paired primary sample ( p = 0.001). The decrease of SOX2 was often seen in patients received chemotherapy, radiotherapy or both ( p = 0.003). Patients with SOX2 high expression in primary glioma had a longer median PFS than those with SOX2 low expression with marginal statistic significance (12.7 vs. 5.4 months, p = 0.083). For cases with SOX2 high expression in the primary glioma, those had SOX2 low expression after recurrence seemed to have worse prognosis as compared to patients with stable SOX2 high expression (PFS: 10.4 vs. 14.9 months, p = 0.036; OS: 27.0 vs 49.5 months, p = 0.005). Conclusions This is the first study comparing the protein expression of SOX2 in recurrent HGG and its paired primary tumor. SOX2 high expression is common in brain HGG, a tendency of decreased SOX2 expression in recurrent gliomas was evidenced. Lower SOX2 expression was seen in those patients who received adjuvant chemotherapy and/or radiotherapy. Patients with low SOX2 expression in primary HGG usually have poorer prognosis, those with SOX2 expression decreased in recurrent HGG had worse outcome.
SOX9+ malignant cells define a poor prognosis subtype of Glioma with tumor-associated macrophage recruitment

Shizhe Yu,Chao Ma,Haoren Wang,Bin Yu,Yi Luan,Zongping Xia

DOI: https://doi.org/10.21203/rs.3.rs-1790668/v1

2022-01-01

Abstract:Abstract Background Gliomas, as the most common aggressive type of primary brain tumors, are highly prevalent and incurable among adults. The dysregulation of transcription factors, including sex determining region Y (SRY)-related high-mobility group (HMG) box (SOX) genes, are considered to be important in cancer development and progression. The aim of our study was to evaluate the effect of SOX9 in the prognosis of glioma. Results We revealed aberrant regulation of most SOX family genes by using 1289 glioma samples from the Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) cohorts. We identified 4 critical genes, SOX3, SOX6, SOX8 and SOX9, -based risk signature model through LASSO regression and a specific SOX9 + cell state with more pronounced malignancy through high-quality single-cell RNA sequencing data analysis. The up regulation of SOX9 and the downregulation of SOX3, SOX6, and SOX8 indicate a decrease in overall survival. The SOX9 + cell state represents a greater proliferative capacity and invasive metastatic properties and is a primary source of attraction for infiltration of bone marrow-derived myeloid (BMM) cells, which are also demonstrated by multicolor immunofluorescence analysis. Conclusions Our study suggests that SOX9 is an independent prognostic and predictive factor for glioma, and the potential interaction between SOX9 + malignant cells and BMM deserves further investigation.
Knockdown of SOX2OT Inhibits the Malignant Biological Behaviors of Glioblastoma Stem Cells Via Up-Regulating the Expression of Mir-194-5p and Mir-122

Rui Su,Shuo Cao,Jun Ma,Yunhui Liu,Xiaobai Liu,Jian Zheng,Jiajia Chen,Libo Liu,Heng Cai,Zhen Li,Lini Zhao,Qianru He,Yixue Xue

DOI: https://doi.org/10.1186/s12943-017-0737-1

IF: 37.3

2017-01-01

Molecular Cancer

Abstract:BACKGROUND:Accumulating evidence has highlighted the potential role of long non-coding RNAs (lncRNAs) in the biological behaviors of glioblastoma stem cells (GSCs). Here, we elucidated the function and possible molecular mechanisms of the effect of lncRNA-SOX2OT on the biological behaviors of GSCs.RESULTS:Real-time PCR demonstrated that SOX2OT expression was up-regulated in glioma tissues and GSCs. Knockdown of SOX2OT inhibited the proliferation, migration and invasion of GSCs, and promoted GSCs apoptosis. MiR-194-5p and miR-122 were down-regulated in human glioma tissues and GSCs, and miR-194-5p and miR-122 respectively exerted tumor-suppressive functions by inhibiting the proliferation, migration and invasion of GSCs, while promoting GSCs apoptosis. Knockdown of SOX2OT significantly increased the expression of miR-194-5p and miR-122 in GSCs. Dual-luciferase reporter assay revealed that SOX2OT bound to both miR-194-5p and miR-122. SOX3 and TDGF-1 were up-regulated in human glioma tissues and GSCs. Knockdown of SOX3 inhibited the proliferation, migration and invasion of GSCs, promoted GSCs apoptosis, and decreased TDGF-1 mRNA and protein expression through direct binding to the TDGF-1 promoter. Over-expression of miR-194-5p and miR-122 decreased the mRNA and protein expression of SOX3 by targeting its 3'UTR. Knockdown of TDGF-1 inhibited the proliferation, migration and invasion of GSCs, promoted GSCs apoptosis, and inhibited the JAK/STAT signaling pathway. Furthermore, SOX3 knockdown also inhibited the SOX2OT expression through direct binding to the SOX2OT promoter and formed a positive feedback loop.CONCLUSION:This study is the first to demonstrate that the SOX2OT-miR-194-5p/miR-122-SOX3-TDGF-1 pathway forms a positive feedback loop and regulates the biological behaviors of GSCs, and these findings might provide a novel strategy for glioma treatment.
Silencing Sox2 Induced Mesenchymal-Epithelial Transition And Its Expression Predicts Liver And Lymph Node Metastasis Of Crc Patients

Xu Han,Xuefeng Fang,Xiaoyan Lou,Dasong Hua,Wenchao Ding,Gregory Foltz,Leroy Hood,Ying Yuan,Biaoyang Lin

DOI: https://doi.org/10.1371/journal.pone.0041335

IF: 3.7

2012-01-01

PLoS ONE

Abstract:SOX2 is an important stem cell marker and plays important roles in development and carcinogenesis. However, the role of SOX2 in Epithelial-Mesenchymal Transition has not been investigated. We demonstrated, for the first time, that SOX2 is involved in the Epithelial-Mesenchymal Transition (EMT) process as knock downof SOX2 in colorectal cancer (CRC) SW620 cells induced a Mesenchymal-Epithelial Transition (MET) process with recognized changes in the expression of key genes involved in the EMT process including E-cadherin and vimentin. In addition, we provided a link between SOX2 activity and the WNT pathway by showing that knock down of SOX2 reduced the WNT pathway activity in colorectal cancer (CRC) cells. We further demonstrated that SOX2 is involved in cell migration and invasion in vitro and in metastasis in vivo for CRC cells, and that the process might be mediated through the MMP2 activity. Finally, an IHC analysis of 44 cases of colorectal cancer patients suggested that SOX2 is a prognosis marker for metastasis of colorectal cancers.
MEOX2-mediated regulation of Cathepsin S promotes cell proliferation and motility in glioma

Ji Wang,Yanming Chen,Qing Wang,Hui Xu,Chunwang Wu,Qianqian Jiang,Guoqing Wu,Honglong Zhou,Zongyu Xiao,Ying Chen,Tan Zhang,Qing Lan

DOI: https://doi.org/10.1038/s41419-022-04845-2

2022-04-01

Cell Death and Disease

Abstract:Abstract Nuclear transcription factor Mesenchyme Homeobox 2 (MEOX2) is a homeobox gene that is originally discovered to suppress the growth of vascular smooth muscle and endothelial cells. However, whether or not it is connected to cancer is yet unknown. Here, we report that MEOX2 functions as a tumor-initiating element in glioma. Bioinformatic analyses of public databases and investigation of MEOX2 expression in patients with glioma demonstrated that MEOX2 was abundant at both mRNA and protein levels in glioma. MEOX2 expression was shown to be inversely linked with the prognosis of glioma patients. MEOX2 inhibition changed the morphology of glioma cells, inhibited cell proliferation and motility, whereas had no effect on cell apoptosis. Besides, silencing MEOX2 also hampered the epithelial-mesenchymal transition (EMT), focal adhesion formation, and F-actin assembly. Overexpression of MEOX2 exhibited opposite effects. Importantly, RNA-sequencing, ChIP-qPCR assay, and luciferase reporter assay revealed Cathepsin S (CTSS) as a novel transcriptional target of MEOX2 in glioma cells. Consistently, MEOX2 causes glioma tumor development in mice and greatly lowers the survival period of tumor-bearing mice. Our findings indicate that MEOX2 promotes tumorigenesis and progression of glioma partially through the regulation of CTSS. Targeting MEOX2-CTSS axis might be a promising alternative for the treatment of glioma.

cell biology
Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme

Maurizio Martini,Roberto Pallini,Giuseppe Luongo,Tonia Cenci,Corrado Lucantoni,Luigi Maria Larocca

DOI: https://doi.org/10.1002/ijc.23805

2008-12-15

Abstract:Alterations in the signal transduction pathways are key mechanisms in the pathogenesis of de novo glioblastoma multiforme (GBM), which are also involved in the resistance to chemo- and radiotherapy. Here, we analyzed the methylation status and mRNA expression of suppressor of cytokine signaling (SOCS)1-2-3, 3 of the most important inhibitory molecules of the signal transduction circuitry, in 46 GBM specimens. The relationship between methylation status of SOCS1-2-3 and clinical outcome was investigated. Using methylation-specific PCR (MS-PCR) and sequencing, after bisulphite modification, we found that the promoter of SOCS1-2-3 was methylated in 24, 6.5 and 35% of GBM, respectively. Real-time analysis showed that in methylated GBM, mRNA expression for SOCS1-2-3 was reduced by 5, 3 and 7-folds, respectively, when compared with unmethylated GBM. Moreover, methylation of SOCS3 promoter significantly associated with an unfavorable clinical outcome (p < 0.0002). Our data suggest that methylation of SOCS3 may be involved in the pathogenesis of GBM and in the resistance of this neoplasm to conventional treatment.
Analysis of SOX9 Expression in Colorectal Cancer.

Bingjian Lue,Yihu Fang,Jing Xu,Lipei Wang,Fangying Xu,Enping Xu,Qiong Huang,Maode Lai

DOI: https://doi.org/10.1309/ajcpw1w8gjbqgcni

2008-01-01

American Journal of Clinical Pathology

Abstract:Our purpose was to investigate the role of SOX9, a novel downstream molecule of beta-catenin, in colorectal cancer. Expression of SOX9 and beta-catenin was detected by immunostaining, quantitative real-time reverse transcription-polymerase chain reaction (Q-PCR), and Western blot in colorectal cancer. The correlation between SOX9 or P-catenin expression and clinicopathologic parameters was also analyzed. Immunostaining, Q-PCR, and Western blot consistently confirmed SOX9 up-regulation in colorectal cancer compared with normal mucosa (P < .05). Immunostaining showed more SOX9+ cells in the lower zone of colonic crypts than in the upper zone (P < .05). Cancers with strong SOX9 immunostaining were significantly associated with a lower 5-year overall survival (40% [17/43] vs low expression, 69% [66/95]; P < .01). The Cox proportional hazards model showed that strong SOX9 expression was an independent adverse prognosticator in colorectal cancer (P < .05). The detection of SOX9 expression might contribute to predicting clinical outcomes for patients with colorectal cancer.
Expression of SOX9 in Colorectal Cancer and Its Significance

方义湖,徐芳英,黄琼,吕炳建,徐恩萍,来茂德

DOI: https://doi.org/10.3969/j.issn.1001-1692.2008.05.009

2008-01-01

Abstract:Objective To investigate the expressions of SOX9 and SOX8 in colorectal cancer and its correlation with the clinopathologic parameters.Methods The expressions of SOX9 and SOX8 were detected with immunohistochemical staining in 226 cases of colorectal cancer and 41 of sporadic adenoma.Results Nuclear staining of SOX8 and SOX9 was found in colorectal tissues.The incidence of SOX9 expression increased sequentially from normal mucosa(9.1%,10/110),peri-cancer mucosa(14.0%,16/114) and adenoma(48.8%,20/41) to cancers(60.1%,113/188)(P0.01).SOX8 expression was absent in normal mucosa and peri-cancer mucosa,but SOX8 was expressed in adenomas(29.3%,12/41) and cancers(15.2%,31/204).SOX9 overexpression(≥++) was only found in colorectal adenomas and cancers(P0.01).SOX9 overexpression in mucinous/signet-ring cell carcinoma was uncommon while SOX8 expression was primarily in mucinous/signet-ring cell carcinoma(P0.01).Both SOX8 and SOX9 expressions were not associated with other clinopathologic parameters including histology grading(P0.05).It was also found that SOX9 overexpression was an independent indicator of adverse prognosis for colorectal cancer(P0.01).Conclusions SOX9 expression is upregulated in colorectal cancers and its overexpression is an independent adverse prognosticator in colorectal cancers.
The SOX2 Response Program in Glioblastoma Multiforme: an Integrated ChIP-seq, Expression Microarray, and Microrna Analysis

Xuefeng Fang,Jae-Geun Yoon,Lisha Li,Wei Yu,Jiaofang Shao,Dasong Hua,Shu Zheng,Leroy Hood,David R Goodlett,Gregory Foltz,Biaoyang Lin

DOI: https://doi.org/10.1186/1471-2164-12-11

IF: 4.547

2011-01-01

BMC Genomics

Abstract:Background SOX2 is a key gene implicated in maintaining the stemness of embryonic and adult stem cells. SOX2 appears to re-activate in several human cancers including glioblastoma multiforme (GBM), however, the detailed response program of SOX2 in GBM has not yet been defined. Results We show that knockdown of the SOX2 gene in LN229 GBM cells reduces cell proliferation and colony formation. We then comprehensively characterize the SOX2 response program by an integrated analysis using several advanced genomic technologies including ChIP-seq, microarray profiling, and microRNA sequencing. Using ChIP-seq technology, we identified 4883 SOX2 binding regions in the GBM cancer genome. SOX2 binding regions contain the consensus sequence wwTGnwTw that occurred 3931 instances in 2312 SOX2 binding regions. Microarray analysis identified 489 genes whose expression altered in response to SOX2 knockdown. Interesting findings include that SOX2 regulates the expression of SOX family proteins SOX1 and SOX18 , and that SOX2 down regulates BEX1 (brain expressed X-linked 1) and BEX2 (brain expressed X-linked 2), two genes with tumor suppressor activity in GBM. Using next generation sequencing, we identified 105 precursor microRNAs (corresponding to 95 mature miRNAs) regulated by SOX2 , including down regulation of miR-143, -145, -253-5p and miR-452. We also show that miR-145 and SOX2 form a double negative feedback loop in GBM cells, potentially creating a bistable system in GBM cells. Conclusions We present an integrated dataset of ChIP-seq, expression microarrays and microRNA sequencing representing the SOX2 response program in LN229 GBM cells. The insights gained from our integrated analysis further our understanding of the potential actions of SOX2 in carcinogenesis and serves as a useful resource for the research community.
Prognostic Potential of Secreted Modular Calcium-Binding Protein 1 in Low-Grade Glioma

Jing Wang,Shu Xia,Jing Zhao,Chen Gong,Qingsong Xi,Wei Sun

DOI: https://doi.org/10.3389/fmolb.2021.666623

IF: 6.113

2021-11-19

Frontiers in Molecular Biosciences

Abstract:Background: Secreted modular calcium-binding protein 1 (SMOC1) belongs to a family of matricellular proteins; it was involved in embryo development, endothelial cell proliferation, angiogenesis, integrin–matrix interactions, cell adhesion, and regulation of glucose metabolism. Previous studies showed that the expression of SMOC1 was increased in some tumors. However, the prognostic value and the biological function of SMOC1 in tumor remain unclear. Methods: In this study, we explored the expression profile and prognostic value of SMOC1 in pan-cancers, especially glioma, via multiple databases, including Oncomine, Gene Expression Profiling Interactive 2, PrognoScan, Kaplan–Meier plotter, and the Chinese Glioma Genome Atlas database. Furthermore, LinkedOmics was used to identify the genes coexpressed with SMOC1 and to perform Kyoto Encyclopedia of Genes and Genomes pathways and Gene Ontology analysis in low-grade glioma (LGG). Also, the Cancer Single-Cell State Atlas database was used to evaluate the correlation between SMOC1 expression and functional state activities in glioma cells. In addition, the Tumor Immune Estimation Resource and TISIDB databases were used to evaluate the correlations between SMOC1 expression and tumor-infiltrating immune cells in the tumor microenvironment. Results: Compared with normal brain tissues, the expression of SMOC1 was increased in LGG tissues. The higher expression of SMOC1 was significantly correlated with better survival of LGG patients. Additionally, functional analyses showed that the SMOC1 coexpressed genes were inhibited in processes such as response to type I interferon and interferon-gamma, lymphocyte-mediated immunity, leukocyte migration, adaptive immune response, neutrophil-mediated immunity, T cell activation, and pathways including EMC–receptor interaction, Th17 cell differentiation, and leukocyte trans -endothelial migration in LGG. Moreover, the expression of SMOC1 was correlated with stemness, hypoxia, EMT, and metastasis of glioma cells. Additionally, the expression of SMOC1 expression was negatively correlated with levels of infiltrating B cells, CD8 + T cells, CD4 + T cells, macrophages, neutrophils and dendritic cells, and gene markers of most immune cells in LGG. Conclusion: Our results suggest that SMOC1 could be a potential biomarker to determine prognosis and might play a specific role in the tumor microenvironment of glioma, thereby influencing the development and progression of glioma. These findings provide some new insights for further investigation.

biochemistry & molecular biology
Oncogenic role of microRNA-19b-3p-mediated SOCS3 in glioma through activation of JAK-STAT pathway

Tao Li,Hong Ge,Qingyan Yang,Junmei Wang,Qian Yin,Hongbin Wang,Gaolei Hou

DOI: https://doi.org/10.1007/s11011-022-01136-9

IF: 3.6551

2022-12-10

Metabolic Brain Disease

Abstract:The altered expression of microRNA (miRNA) has been implicated in glioma. Here, the current study aimed to clarify the oncogenic effects of miR-19b-3p on cellular processes of glioma and to elucidate the underlying mechanism associated with SOCS3 and the JAK-STAT signaling pathway. Differentially expressed genes related to glioma were initially identified via microarray analysis. Twenty-five glioma patients were selected for clinical data collection, while additional 12 patients with traumatic brain injuries were selected as controls. Cell senescence was assessed by β-galactosidase staining, proliferation by MTT assay and apoptosis by flow cytometry following gain- and/or loss-of-function of miR-19b-3p or SOCS3 . Glioma xenograft mouse model was developed through subcutaneous injection to nude mice to provide evidence in vivo. The glioma patients exhibited overexpressed miR-19b-3p and poorly-expressed SOCS3 . SOCS3 was identified as a target gene of miR-19b-3p through dual-luciferase reporter gene assay. miR-19b-3p repressed SOCS3 expression and activated the JAK-STAT signaling pathway. Furthermore, miR-19b-3p inhibition promoted apoptosis and senescence, and suppressed cell proliferation through inactivation of the JAK-STAT signaling pathway and up-regulation of SOCS3 . The reported regulatory axis was validated in nude mice as evidenced by suppressed tumor growth. Taken together, this study demonstrates that miR-19b-3p facilitates glioma progression via activation of the JAK-STAT signaling pathway by targeting SOCS3 , highlighting a novel therapeutic target for glioma treatment.

neurosciences,endocrinology & metabolism
Loss of SOCS3 in myeloid cells prolongs survival in a syngeneic model of glioma

Braden C McFarland,Margaret P Marks,Amber L Rowse,Samuel C Fehling,Magda Gerigk,Hongwei Qin,Etty N Benveniste

DOI: https://doi.org/10.18632/oncotarget.7992

2016-04-12

Oncotarget

Abstract:In glioma, microglia and macrophages are the largest population of tumor-infiltrating cells, referred to as glioma associated macrophages (GAMs). Herein, we sought to determine the role of Suppressor of Cytokine Signaling 3 (SOCS3), a negative regulator of Signal Transducer and Activator of Transcription 3 (STAT3), in GAM functionality in glioma. We utilized a conditional model in which SOCS3 deletion is restricted to the myeloid cell population. We found that SOCS3-deficient bone marrow-derived macrophages display enhanced and prolonged expression of pro-inflammatory M1 cytokines when exposed to glioma tumor cell conditioned medium in vitro. Moreover, we found that deletion of SOCS3 in the myeloid cell population delays intracranial tumor growth and increases survival of mice bearing orthotopic glioma tumors in vivo. Although intracranial tumors from mice with SOCS3-deficient myeloid cells appear histologically similar to control mice, we observed that loss of SOCS3 in myeloid cells results in decreased M2 polarized macrophage infiltration in the tumors. Furthermore, loss of SOCS3 in myeloid cells results in increased CD8+ T-cell and decreased regulatory T-cell infiltration in the tumors. These findings demonstrate a beneficial effect of M1 polarized macrophages on suppressing glioma tumor growth, and highlight the importance of immune cells in the tumor microenvironment.
MEOX2 promotes glioma growth and temozolomide chemoresistance

Tengfei Li,Kaijun Sun,Wanchun Yang,Meiling Zhang,Wentao Feng,Siliang Chen,Mingrong Zuo,Qiuyun Yuan,Yanhui Liu,Mina Chen

DOI: https://doi.org/10.1016/j.jpha.2023.12.002

Abstract:Image 1.
ChIP-seq and Functional Analysis of the SOX2 Gene in Colorectal Cancers

Xuefeng Fang,Wei Yu,Lisha Li,Jiaofang Shao,Na Zhao,Qiyun Chen,Zhiyun Ye,Sheng-Cai Lin,Shu Zheng,Biaoyang Lin

DOI: https://doi.org/10.1089/omi.2010.0053

2010-01-01

OMICS A Journal of Integrative Biology

Abstract:SOX2 is an HMG box containing transcription factor that has been implicated in various types of cancer, but its role in colorectal cancers (CRC) has not been studied. Here we show that SOX2 is overexpressed in CRC tissues compared with normal adjacent tissues using immunohistochemical staining and RT-PCR. We also observed an increased SOX2 expression in nucleus of colorectal cancer tissues (46%, 14/30 cases vs. 7%, 2/30 adjacent tissues). Furthermore, knockdown of SOX2 in SW620 colorectal cancer cells decreased their growth rates in vitro cell line, and in vivo in xenograft models. ChIP-Seq analysis of SOX2 revealed a consensus sequence of wwTGywTT. An integrated expression profiling and ChIP-seq analysis show that SOX2 is involved in the BMP signaling pathway, steroid metabolic process, histone modifications, and many receptor-mediated signaling pathways such as IGF1R and ITPR2 (Inositol 1,4,5-triphosphate receptor, type 2).
The expression of moesin in astrocytoma: correlation with pathologic grade and poor clinical outcome

Ming Wu,Ding-yang Liu,Xian-rui Yuan,Qing Liu,Xin-jun Jiang,Dun Yuan,Jun Huang,Xue-jun Li,Zhi-quan Yang

DOI: https://doi.org/10.1007/s12032-012-0372-z

2013-01-01

Medical Oncology

Abstract:Moesin, a member of the ERM family, acts as a linker between the actin cytoskeleton and the plasma membrane and plays a key role in the control of cell morphology, motility, adhesion and other processes of tumourigenesis. The expression pattern and clinical significance of moesin in astrocytoma remain unknown. In this study, we used RT-PCR to systematically investigate the expression of moesin in 49 astrocytomas of different pathological grade and 6 normal brain tissues. We found that the mRNA expression levels of moesin in astrocytomas were significantly higher in comparison with normal brain tissues. Furthermore, moesin up-regulation was correlated with pathological grade of astrocytomas. Subsequently, we tested 112 astrocytomas and 14 normal brain tissues by immunohistochemistry. Similar results were also confirmed. Univariate and multivariate survival analysis were used to determine the correlations of moesin expression with overall survival and progression-free survival. Our results showed the expression of moesin was strongly negatively correlated with the patient progression-free survival and overall survival. These results suggest moesin protein involved in the genesis and progression of astrocytomas and might be regarded as an independent predictor of poor prognosis.
Stem Cell Markers in Neoplasms and their Relationship with Progression-free and Overall Survival in Patients with Recurrence

Aldo Eguiluz-Melendez,Carmen Rubio-Osornio,Artemio Rosiles-Abonce,Cesar Mendoza,Miryam Ramírez-Ordás,Romina Rivera-Cañas,Martha Tena-Suck,Juan Luis Gómez-Amador,Sergio Moreno-Jimenez

DOI: https://doi.org/10.2174/0115748928277672240429065526

2024-05-09

Abstract:Background: Gliomas account for 30% of primary brain tumors in adults, and despite the scientific progress in the field, recurrence is prevalent. Glioma Stem Cells (GSCs) can generate tumor cells in vivo and in vitro and they are associated with treatment resistance, tumor progression, and recurrence. Furthermore, the expression of SOX transcription factors (SOX1, SOX2, SOX9) in these cells is responsible for maintaining an oncogenic genotype and is associated with an aggressive tumor phenotype. The relationship between SOX transcription factors and their prognostic role in recurrent gliomas has not been described in detail. Therefore, we set out to describe the relationship between SOX expression and Progression-free Survival (PFS) and Overall Survival (OS) in patients with recurrent gliomas. Methods: In this observational study, we have retrospectively analyzed 69 patients, of which 20 met the inclusion criteria. The clinical, radiological, and histopathological findings have been described, and survival analysis has been performed according to SOX expression for PFS and OS. Results: We found SOX1, SOX2, and SOX9 to show a non-statistically significant trend with increasing histopathological grade, co-expressed with Ki67, a cell proliferation factor. Conclusion: There has been found an inversely proportional correlation between the degree of immunopositivity of SOX1 and OS. A higher SOX1 immunopositivity could predict a worse clinical prognosis. There has also been found an interaction between a pluripotent genotype (GSC) and cell proliferation.
Role of COL6A2 in malignant progression and temozolomide resistance of glioma

Xia Hong,Jingjing Zhang,Jianmin Zou,Jiecai Ouyang,Boan Xiao,Peng Wang,Xiaobin Peng

DOI: https://doi.org/10.1016/j.cellsig.2022.110560

IF: 4.85

2022-12-14

Cellular Signalling

Abstract:Background Gliomas are one of the most common primary malignant tumors of the central nervous system, and have an unfavorable prognosis. Even combining precise surgery, chemotherapy and radiotherapy, the survival rate is still unsatisfactory. Chemotherapy resistance is one of main reasons for its adverse prognosis. As shown by several studies, glioma stem cells (GSCs) were correlated with radiotherapy/chemotherapy resistance and high relapse rate. This study aimed to find a new biomarker related to GSCs and chemotherapy resistance. Methods TCGA, CGGA, GSE16011, GSE23806 and GDSC datasets were used to screen the genes related to GSCs, Temozolomide (TMZ) resistance, and survival. In the TCGA, GTEx, GSE16011 and CGGA datasets, mRNA level, prognostic value, and correlation with immune infiltration in the selected genes were analyzed through methods including Kaplan-Meier analysis, Cox analysis, the ESTIMATE algorithm, and the CIBERSORT algorithm. The expression of COL6A2 mRNA and protein in different groups was detected by RT-qPCR and western blot. A MTT assay and flow cytometry were used to measure the effect of COL6A2 on proliferation and apoptosis of glioma cells. Results COL6A2 was positively correlated with glioma stemness and TMZ resistance. Its expression was up-regulated in GBM, and high expression was correlated with adverse prognosis. As shown by Cox analysis, COL6A2 was an independent prognostic factor for glioma. COL6A2 mRNA was increased with the glioma grade. It was over-expressed in MGMT non-methylation and IDH wild-type specimens. The results of in vitro experiments showed that COL6A2 promots proliferation of glioma cells and inhibits their apoptosis. Meanwhile, the expression of COL6A2 in TMZ-resistant glioma cells was significantly higher than that in ordinary glioma cells. As shown by GO and KEGG pathway analysis, COL6A2 was correlated with glioma proliferation, migration, invasion, and immunity. In particular, it was significantly positively correlated with PD-1, PD-L2, PD-L1, B7-H3, CTLA-4, IDO1 and TIM-3 expression, further verifying that it may play an important role in immune response. In addition, COL6A2 might influence immune cell infiltration in the glioma microenvironment. Conclusion COL6A2 high-expression is an indicator for adverse glioma prognosis, and is correlated with TMZ-resistant and immune response. Meanwhile, it may be a prospective biomarker for treatment.

cell biology
QSOX1 Modulates Glioblastoma Cell Proliferation and Migration In Vitro and Invasion In Vivo

Reetika Dutt,Colin Thorpe,Deni S. Galileo

DOI: https://doi.org/10.3390/cancers16213620

2024-10-27

Cancers

Abstract:Background: Quiescin Sulfhydryl Oxidase 1 (QSOX1) is an enzyme that catalyzes the oxidation of free thiols to generate disulfide bonds in a variety of proteins, including the cell surface and extracellular matrix. QSOX1 has been reported to be upregulated in a number of cancers, and the overexpression of QSOX1 has been correlated with aggressive cancers and poor patient prognosis. Glioblastoma (GBM) brain cancer has been practically impossible to treat effectively, with cells that rapidly invade normal brain tissue and escape surgery and other treatment. Thus, there is a crucial need to understand the multiple mechanisms that facilitate GBM cell invasion and to determine if QSOX1 is involved. Methods and Results: Here, we investigated the function of QSOX1 in human glioblastoma cells using two cell lines derived from T98G cells, whose proliferation, motility, and invasiveness has been shown by us to be dependent on disulfide bond-containing adhesion and receptor proteins, such as L1CAM and the FGFR. We lentivirally introduced shRNA to attenuate the QSOX1 protein expression in one cell line, and a Western blot analysis confirmed the decreased QSOX1 expression. A DNA content/cell cycle analysis using flow cytometry revealed 27% fewer knockdown cells in the S-phase of the cell cycle, indicating a reduced proliferation. A cell motility analysis utilizing our highly quantitative SuperScratch time-lapse microscopy assay revealed that knockdown cells migrated more slowly, with a 45% decrease in migration velocity. Motility was partly rescued by the co-culture of knockdown cells with control cells, indicating a paracrine effect. Surprisingly, knockdown cells exhibited increased motility when assayed using a Transwell migration assay. Our novel chick embryo orthotopic xenograft model was used to assess the in vivo invasiveness of knockdown vs. control cells, and tumors developed from both cell types. However, fewer invasive knockdown cells were observed after about a week. Conclusions: Our results indicate that an experimental reduction in QSOX1 expression in GBM cells leads to decreased cell proliferation, altered in vitro migration, and decreased in vivo invasion.

oncology
The Role of SOX2 Overexpression in Prognosis of Patients with Solid Tumors

Shengjie Wang,Xinli Liu,Ying Chen,Xiaozhen Zhan,Tujin Wu,Bing Chen,Guangwen Sun,Songling Yan,Lin Xu

DOI: https://doi.org/10.1097/md.0000000000019604

IF: 1.6

2020-01-01

Medicine

Abstract:Abstract Background: Many studies have been done to reported the value of SRY-related HMG-box Gene 2 (SOX2) in prognosis of solid tumors. But results were not particularly consistent among these studies because of the limitations of the small sample data. Methods: We searched relevant studies published before November 2018 by PubMed, Web of Science and EMBASE. In this meta-analysis, hazard ratio (HR) values for overall survival (OS) were cumulatively pooled and quantitatively analyzed. Results: A meta-analysis based on 12 studies with 3318 patients was conducted to assess the potential correlation between SOX2 overexpression and OS in human solid tumors. A total of 12 studies (n = 3318) were assessed in the meta-analysis. It suggested that the high expression of SOX2 obviously indicates poor survival and prognosis in both univariate and multivariate analysis. In the univariate analysis, the combined HR for OS was 1.66 (95% confidence interval [CI]: 1.46–1.89, P < .001). The pooled HR of multivariate analysis for OS was 1.51 (95% confidence interval [CI]: 1.32–1.71, P < .001). Conclusions: This meta-analysis indicated that the high expression level of SOX2 is significantly associated with a decline in survival of human with solid tumors. On the basis of the expression level in solid tumors, SOX2 is expected to be a meaningful prognostic biomarker and effective therapeutic target.
Quiescin Sulfhydryl Oxidase 2 Overexpression Predicts Poor Prognosis and Tumor Progression in Patients With Colorectal Cancer: A Study Based on Data Mining and Clinical Verification

Tao Jiang,Li Zheng,Xia Li,Jia Liu,Hu Song,Yixin Xu,Chenhua Dong,Lianyu Liu,Hongyu Wang,Shuai Wang,Renhao Wang,Jun Song

DOI: https://doi.org/10.3389/fcell.2021.678770

IF: 5.5

2021-11-10

Frontiers in Cell and Developmental Biology

Abstract:Background: As a member of the atypical thiol oxidase family, quiescin sulfhydryl oxidase 2 (QSOX2) has been reported to play an important role in several biological processes, but the expression and function of QSOX2 in colorectal cancer (CRC) remains elusive. Methods: The difference of QSOX2 expression, and its relationship with clinicopathological features and prognosis in CRC, was analyzed by bioinformatic analysis and validated by clinical CRC specimen cohort. The functional characterization of QSOX2 was detected via in vitro and vivo experiments in CRC cell lines, while the potential signaling pathways were predicted by Gene Set Enrichment Analysis (GSEA). Results: Our data based on bioinformatical analysis and clinical validation demonstrated that the expression of QSOX2 in CRC tissues was significantly upregulated. Additionally, the chi-square test, logistic regression analysis, and Fisher’s exact test showed that QSOX2 overexpression was significantly correlated with advanced clinicopathological parameters, such as pathological stage and lymph node metastasis. The Kaplan–Meier curves and univariate Cox regression model showed that QSOX2 overexpression predicts poor overall survival (OS) and disease-free survival (DFS) in CRC patients. More importantly, multivariate Cox regression model showed that QSOX2 overexpression could serve as an independent factor for CRC patients. In vitro and vivo data showed that the proliferation and metastasis ability of CRC cells were suppressed on condition of QSOX2 inhibition. In addition, GSEA showed that the QSOX2 high expression phenotype has enriched multiple potential cancer-related signaling pathways. Conclusion: QSOX2 overexpression is strongly associated with malignant progression and poor oncological outcomes in CRC. QSOX2 might act as a novel biomarker for prognosis prediction and a new target for biotherapy in CRC.

cell biology,developmental biology

MOESM1 of Glioma SOX2 Expression Decreased after Adjuvant Therapy

Glioma SOX2 Expression Decreased after Adjuvant Therapy.

SOX9+ malignant cells define a poor prognosis subtype of Glioma with tumor-associated macrophage recruitment

Knockdown of SOX2OT Inhibits the Malignant Biological Behaviors of Glioblastoma Stem Cells Via Up-Regulating the Expression of Mir-194-5p and Mir-122

Silencing Sox2 Induced Mesenchymal-Epithelial Transition And Its Expression Predicts Liver And Lymph Node Metastasis Of Crc Patients

MEOX2-mediated regulation of Cathepsin S promotes cell proliferation and motility in glioma

Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme

Analysis of SOX9 Expression in Colorectal Cancer.

Expression of SOX9 in Colorectal Cancer and Its Significance

The SOX2 Response Program in Glioblastoma Multiforme: an Integrated ChIP-seq, Expression Microarray, and Microrna Analysis

Prognostic Potential of Secreted Modular Calcium-Binding Protein 1 in Low-Grade Glioma

Oncogenic role of microRNA-19b-3p-mediated SOCS3 in glioma through activation of JAK-STAT pathway

Loss of SOCS3 in myeloid cells prolongs survival in a syngeneic model of glioma

MEOX2 promotes glioma growth and temozolomide chemoresistance

ChIP-seq and Functional Analysis of the SOX2 Gene in Colorectal Cancers

The expression of moesin in astrocytoma: correlation with pathologic grade and poor clinical outcome

Stem Cell Markers in Neoplasms and their Relationship with Progression-free and Overall Survival in Patients with Recurrence

Role of COL6A2 in malignant progression and temozolomide resistance of glioma

QSOX1 Modulates Glioblastoma Cell Proliferation and Migration In Vitro and Invasion In Vivo

The Role of SOX2 Overexpression in Prognosis of Patients with Solid Tumors

Quiescin Sulfhydryl Oxidase 2 Overexpression Predicts Poor Prognosis and Tumor Progression in Patients With Colorectal Cancer: A Study Based on Data Mining and Clinical Verification